Regulatory Role of RNA N6-Methyladenosine Modification in Bone Biology and Osteoporosis
Authors:
Open Access
- 10 January 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 10, 911
Abstract
Osteoporosis is a metabolic skeletal disorder in which bone mass is depleted and bone structure is destroyed to the degree that bone becomes fragile and prone to fractures. Emerging evidence suggests that N6-methyladenosine (m6A) modification, a novel epitranscriptomic marker, has a significant role in bone development and metabolism. M6A modification not only participates in bone development, but also plays important roles as writers and erasers in the osteoporosis. M6A methyltransferase METTL3 and demethyltransferase FTO involves in the delicate process between adipogenesis differentiation and osteogenic differentiation, which is important for the pathological development of osteoporosis. Conditional knockdown of the METTL3 in bone marrow stem cells (BMSCs) could suppress PI3K-Akt signaling, limit the expression of bone formation-related genes (such as Runx2 and Osterix), restrain the expression of vascular endothelial growth factor (VEGF) and down-regulate the decreased translation efficiency of parathyroid hormone receptor-1 mRNA. Meanwhile, knockdown of the METTL3 significantly promoted the adipogenesis process and janus kinase 1 (JAK1) protein expression via an m6A-dependent way. Specifically, there was a negative correlation between METTL3 expression and porcine BMSCs adipogenesis. The evidence above suggested that the relationship between METTL3 expression and adipogenesis was inverse, and osteogenesis was positive, respectively. Similarly, FTO regulated for BMSCs fate determination during osteoporosis through the GDF11-FTO-PPARγ axis, prompting the shift of MSC lineage commitment to adipocyte and inhibiting bone formation during osteoporosis. In this systematic review, we summarize the most up-to-date evidence of m6A RNA modification in osteoporosis and highlight the potential role of m6A in prevention, treatment, and management of osteoporosis.Keywords
This publication has 95 references indexed in Scilit:
- The effect of FTO variation on increased osteoarthritis risk is mediated through body mass index: a mendelian randomisation studyAnnals of the Rheumatic Diseases, 2014
- Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop CodonsCell, 2012
- Disorders of Bone RemodelingAnnual Review of Pathology: Mechanisms of Disease, 2011
- The Fat Mass and Obesity Associated Gene FTO Functions in the Brain to Regulate Postnatal Growth in MicePLOS ONE, 2010
- The genetics of obesity: FTO leads the wayTrends in Genetics, 2010
- Powerful Bivariate Genome-Wide Association Analyses Suggest the SOX6 Gene Influencing Both Obesity and Osteoporosis Phenotypes in MalesPLOS ONE, 2009
- Lean Mass and Not Fat Mass Is Associated With Male Proximal Femur StrengthJournal of Bone and Mineral Research, 2008
- Genome-Wide Association Scan Shows Genetic Variants in the FTO Gene Are Associated with Obesity-Related TraitsPLOS Genetics, 2007
- Relationship of Obesity with OsteoporosisThe Journal of Clinical Endocrinology & Metabolism, 2007
- Is a gene important for bone resorption a candidate for obesity? An association and linkage study on the RANK (receptor activator of nuclear factor-κB) gene in a large Caucasian sampleHuman Genetics, 2006